日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Treatment-specific prognostic performance of ELN 2022, ELN 2024, and Beat AML 2024: a real-world AML validation study

ELN 2022、ELN 2024 和 Beat AML 2024 治疗特异性预后性能:一项真实世界 AML 验证研究

Kewan, Tariq; Alkabbani, Oudai; Zureigat, Hadil; He, Rong; Jevremovic, Dragan; Greipp, Patricia; Saliba, Antoine; Matin, Aasiya; Torghabeh, Mehrdad Hefazi; Mangaonkar, Abishek; Gangat, Naseema; Hogan, William; Patnaik, Mrinal; Alkhateeb, Hassan; Yi, Cecilia Arana; Foran, James; Litzow, Mark; Shah, Mithun; Begna, Kebede; Al-Kali, Aref

Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent

梅奥诊所针对接受维奈托克联合去甲基化药物治疗的新诊断急性髓系白血病患者的遗传风险模型

Gangat, Naseema; Elbeih, Azeem; Ghosoun, Nour; McCullough, Kristen; Aperna, Fnu; Johnson, Isla M; Abdelmagid, Maymona; Al-Kali, Aref; Alkhateeb, Hassan B; Begna, Kebede H; Elliott, Michelle; Mangaonkar, Abhishek; Matin, Aasiya; Saliba, Antoine N; Hefazi Torghabeh, Mehrdad; Litzow, Mark R; Hogan, William; Shah, Mithun; Patnaik, Mrinal M; Pardanani, Animesh; Badar, Talha; Murthy, Hemant; Foran, James; Palmer, Jeanne; Sproat, Lisa; Khera, Nandita; Arana Yi, Cecilia; Yates, Samuel; Sneider, Abigail; Dworkin, Emily; Patel, Anand A; Bazinet, Alexandre; Senapati, Jayastu; Bataller, Alex; DiNardo, Courtney; Kadia, Tapan; Tefferi, Ayalew

Outcomes of attenuated dose fludarabine and melphalan based conditioning regimen in patients undergoing allogeneic stem cell transplant: a propensity score-matched analysis

减量氟达拉滨和美法仑预处理方案在接受异基因造血干细胞移植患者中的疗效:倾向评分匹配分析

Baranwal, Anmol; Kassis, Rabee; Hassan, Khalil; Kutzke, Jade; Bartoo, Gabriel; Wolf, Robert; Matin, Aasiya; Hefazi Torghabeh, Mehrdad; Mangaonkar, Abhishek; Litzow, Mark R; Shah, Mithun V; Hogan, William J; Dingli, David; Alkhateeb, Hassan B

Bronchodilator Response: Utility and implications in patients undergoing hematopoietic stem cell transplantation

支气管扩张剂反应:在接受造血干细胞移植的患者中的应用及意义

Eggleston, Reid H; Torghabeh, Mehrdad Hefazi; Niven, Alexander S; Lim, Kaiser G; Pennington, Kelly M; Hogan, William J; Yadav, Hemang

Clinical Outcome and Molecular Profile in Patients with DDX41 Mutation Hot-Spots

DDX41突变热点患者的临床结果和分子特征

Toumeh, Nadia; Jabban, Yazan; Nanaa, Ahmad; He, Rong; Viswanatha, David; Jevremovic, Dragan; Foran, James M; Arana Yi, Cecilia Y; Saliba, Antoine N; Hefazi Torghabeh, Mehrdad; Hogan, William J; Shah, Mithun V; Mangaonkar, Abhishek A; Patnaik, Mrinal M; Alkhateeb, Hassan B; Al-Kali, Aref

Optimized CART Cell Therapy for Metastatic Aggressive Thyroid Cancer

针对转移性侵袭性甲状腺癌的优化CAR-T细胞疗法

Manriquez Roman, Claudia; Siegler, Elizabeth L; Gleba, Justyna J; Huynh, Truc N; DeFranco, Grace E; Alasonyalilar Demirer, Aylin; Pawlush, Matthew L; Redig, Michael; Klinge, Skyeler M; Mai, Long K; Miller, James L; Miller, Erin E; Kimball, Brooke L; Tapper, Erin E; Sakemura, R Leo; Stewart, Carli M; Can, Ismail; Sirpilla, Olivia L; Feigin, Jennifer M; Yun, Kun; Gutierrez Ruiz, Omar L; Xia, Hong; Hefazi Torghabeh, Mehrdad; Schick, Kendall J; Ogbodo, Ekene J; Olivier, Gloria; Qiu, Yushi; Smallridge, Robert C; Zubair, Abba; Tun, Han W; Copland, John A; Kenderian, Saad S

Characterisation and prognostic impact Of ZRSR2 mutations in myeloid neoplasms

ZRSR2突变在髓系肿瘤中的特征及预后影响

Yacout, Mahmoud; Katamesh, Bahga; Jabban, Yazan; He, Rong; Viswanatha, David; Jevremovic, Dragan; Greipp, Patricia; Bessonen, Kurt; Palmer, Jeanne; Foran, James; Saliba, Antoine; Hefazi-Torghabeh, Mehrdad; Begna, Kebede; Hogan, William; Patnaik, Mrinal; Shah, Mithun; Alkhateeb, Hassan; Al-Kali, Aref

Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent

克拉屈滨联合阿糖胞苷联合维奈克拉治疗复发或对维奈克拉联合去甲基化药物无效的急性髓系白血病

Steinauer, Nickolas; McCullough, Kristen; Al-Kali, Aref; Alkhateeb, Hassan B; Begna, Kebede H; Mangaonkar, Abhishek A; Saliba, Antoine N; Torghabeh, Mehrdad; Litzow, Mark R; Hogan, William J; Shah, Mithun; Patnaik, Mrinal M; Pardanani, Animesh; Badar, Talha; Murthy, Hemant; Foran, James; Yi, Cecilia Arana; Tefferi, Ayalew; Gangat, Naseema

Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia

急性髓系白血病IDH1/2抑制剂单药治疗后疗效和生存的分子预测因子

Gangat, Naseema; McCullough, Kristen; Abdelmagid, Maymona; Karrar, Omer; Powell, Marissa; Al-Kali, Aref; Alkhateeb, Hassan; Begna, Kebede; Mangaonkar, Abhishek; Saliba, Antoine; Torghabeh, Mehrdad Hefazi; Litzow, Mark; Hogan, William; Shah, Mithun; Patnaik, Mrinal; Pardanani, Animesh; Badar, Talha; Foran, James; Palmer, Jeanne; Sproat, Lisa; Yi, Cecilia Arana; Tefferi, Ayalew

FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(DEK::NUP214): the Mayo Clinic experience

FLT3抑制剂可能提高携带t(6;9)(DEK::NUP214)易位的急性髓系白血病患者的缓解率:梅奥诊所的经验

Csizmar, Clifford M; Saliba, Antoine N; Greipp, Patricia T; Alkhateeb, Hassan; Begna, Kebede H; Foran, James M; Gangat, Naseema; Hogan, William J; Hook, C Christopher; Litzow, Mark R; Mangaonkar, Abhishek A; Palmer, Jeanne M; Pardanani, Animesh; Shah, Mithun V; Tefferi, Ayalew; Torghabeh, Mehrdad Hefazi; Wolanskyj-Spinner, Alexandra P; Patnaik, Mrinal M; Kaufmann, Scott H; Al-Kali, Aref